Cybin Partners with Thermo Fisher Scientific to Advance CYB003 for Major Depressive Disorder

Cybin Inc., a clinical-stage biopharmaceutical company, has announced a strategic partnership with Thermo Fisher Scientific to support the Phase 3 clinical supply and potential commercial manufacturing of CYB003, its proprietary deuterated psilocin treatment aimed at major depressive disorder (MDD). This collaboration extends Cybin's existing U.S.-based manufacturing capabilities, with Thermo Fisher Scientific managing drug substance production in South Carolina and capsule manufacturing in Ohio.

The significance of this partnership is underscored by the FDA's Breakthrough Therapy Designation awarded to CYB003 in March 2024, recognizing its potential to address a serious condition with unmet medical needs. The ongoing Phase 3 PARADIGM trial builds on encouraging Phase 2 results, which demonstrated a 100% response rate and a 71% remission rate following two 16 mg doses of CYB003.

This development is a pivotal moment for the psychedelic and mental health industries, as it not only highlights the therapeutic potential of psychedelic-based treatments but also showcases the growing collaboration between biopharmaceutical companies and global scientific leaders to bring innovative solutions to market. The partnership between Cybin and Thermo Fisher Scientific could accelerate the availability of CYB003, offering hope to millions suffering from MDD worldwide.

For further details on Cybin's groundbreaking work and its partnership with Thermo Fisher Scientific, visit https://ibn.fm/Q29gC.